Margit Kapás

753 total citations
14 papers, 608 citations indexed

About

Margit Kapás is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, Margit Kapás has authored 14 papers receiving a total of 608 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Cellular and Molecular Neuroscience and 5 papers in Pharmacology. Recurrent topics in Margit Kapás's work include Neurotransmitter Receptor Influence on Behavior (5 papers), Schizophrenia research and treatment (5 papers) and Neuroscience and Neuropharmacology Research (4 papers). Margit Kapás is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (5 papers), Schizophrenia research and treatment (5 papers) and Neuroscience and Neuropharmacology Research (4 papers). Margit Kapás collaborates with scholars based in Hungary, United States and Sweden. Margit Kapás's co-authors include Béla Kiss, Zsolt Szombathelyi, Katalin Sághy, György Domány, István Gyertyán, Károly Tihanyi, Judit Laszy, I. Laszlovszky, Vera Ádám‐Vizi and Balázs Gulyás and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Psychopharmacology and Bioorganic & Medicinal Chemistry Letters.

In The Last Decade

Margit Kapás

14 papers receiving 589 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Margit Kapás Hungary 10 289 260 176 115 65 14 608
Zsolt Némethy Hungary 10 229 0.8× 265 1.0× 263 1.5× 100 0.9× 41 0.6× 20 638
Yasufumi Uwahodo Japan 12 243 0.8× 309 1.2× 308 1.8× 96 0.8× 124 1.9× 18 794
Zsolt Szombathelyi Hungary 15 362 1.3× 488 1.9× 338 1.9× 133 1.2× 145 2.2× 34 969
Piotr Stępnicki Finland 9 163 0.6× 174 0.7× 226 1.3× 70 0.6× 48 0.7× 18 593
Tomoko Horisawa Japan 8 283 1.0× 242 0.9× 157 0.9× 99 0.9× 36 0.6× 10 558
Judit Laszy Hungary 10 179 0.6× 275 1.1× 184 1.0× 69 0.6× 75 1.2× 18 528
Kumiko Tokuda Japan 3 259 0.9× 182 0.7× 118 0.7× 92 0.8× 56 0.9× 6 507
Magda Kondej Poland 6 157 0.5× 158 0.6× 199 1.1× 58 0.5× 36 0.6× 10 515
Katalin Sághy Hungary 14 203 0.7× 317 1.2× 221 1.3× 74 0.6× 99 1.5× 22 577
M.B. Assié France 8 103 0.4× 281 1.1× 170 1.0× 115 1.0× 42 0.6× 16 452

Countries citing papers authored by Margit Kapás

Since Specialization
Citations

This map shows the geographic impact of Margit Kapás's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margit Kapás with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margit Kapás more than expected).

Fields of papers citing papers by Margit Kapás

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margit Kapás. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margit Kapás. The network helps show where Margit Kapás may publish in the future.

Co-authorship network of co-authors of Margit Kapás

This figure shows the co-authorship network connecting the top 25 collaborators of Margit Kapás. A scholar is included among the top collaborators of Margit Kapás based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margit Kapás. Margit Kapás is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Periclou, Antonia, et al.. (2020). Population Pharmacokinetics of Cariprazine and its Major Metabolites. European Journal of Drug Metabolism and Pharmacokinetics. 46(1). 53–69. 20 indexed citations
2.
Laszlovszky, I., Béla Kiss, Ágota Barabássy, Margit Kapás, & György Németh. (2019). [Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms].. PubMed. 21(3). 103–118. 2 indexed citations
3.
Periclou, Antonia, Susan Willavize, Julie Passarell, et al.. (2019). Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania. Clinical and Translational Science. 13(2). 362–371. 7 indexed citations
4.
Girgis, Ragy R., Mark Slifstein, Deepak Cyril D’Souza, et al.. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology. 233(19-20). 3503–3512. 97 indexed citations
5.
Kapás, Margit, et al.. (2016). Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Design Development and Therapy. 327–327. 68 indexed citations
6.
Ágai-Csongor, Éva, György Domány, János Galambos, et al.. (2012). Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors. Bioorganic & Medicinal Chemistry Letters. 22(10). 3437–3440. 74 indexed citations
7.
Gyertyán, István, Béla Kiss, Katalin Sághy, et al.. (2011). Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochemistry International. 59(6). 925–935. 119 indexed citations
8.
Takács‐Novák, Krisztina, et al.. (2008). Physico-chemical characterization of a novel group of dopamine D3/D2 receptor ligands, potential atypical antipsychotic agents. Journal of Pharmaceutical and Biomedical Analysis. 48(3). 678–684. 10 indexed citations
9.
Gyertyán, István, Katalin Sághy, Judit Laszy, et al.. (2008). Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn-Schmiedeberg s Archives of Pharmacology. 378(5). 529–539. 50 indexed citations
10.
Ágai-Csongor, Éva, et al.. (2007). Sensitive LC–MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 48(2). 388–397. 19 indexed citations
11.
Gyertyán, István, Béla Kiss, Krisztina Gál, et al.. (2006). Effects of RGH-237 [N-{4-[4-(3-Aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an Orally Active, Selective Dopamine D3 Receptor Partial Agonist in Animal Models of Cocaine Abuse. Journal of Pharmacology and Experimental Therapeutics. 320(3). 1268–1278. 29 indexed citations
12.
Kapás, Margit, et al.. (2001). An HPLC/UV method for the determination of RGH-1756 in dog and rat plasma. Journal of Pharmaceutical and Biomedical Analysis. 24(5-6). 913–920. 1 indexed citations
13.
Gulyás, Balázs, Vera Ádám‐Vizi, Béla Kiss, et al.. (2000). Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Research Bulletin. 53(3). 245–254. 111 indexed citations
14.
Kapás, Margit, et al.. (1996). High-performance liquid chromatographic method for the determination of RGH-5002 in human, rabbit and rat plasma. Journal of Pharmaceutical and Biomedical Analysis. 14(8-10). 1233–1239. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zsolt Némethy Breakdown of academic impact, for papers by Yasufumi Uwahodo Breakdown of academic impact, for papers by Zsolt Szombathelyi Breakdown of academic impact, for papers by Piotr Stępnicki Breakdown of academic impact, for papers by Tomoko Horisawa Breakdown of academic impact, for papers by Judit Laszy Breakdown of academic impact, for papers by Kumiko Tokuda Breakdown of academic impact, for papers by Magda Kondej Breakdown of academic impact, for papers by Katalin Sághy Breakdown of academic impact, for papers by M.B. Assié
Rankless by CCL
2026